DK2175851T3 - Biofilmbehandling - Google Patents

Biofilmbehandling

Info

Publication number
DK2175851T3
DK2175851T3 DK08772643.6T DK08772643T DK2175851T3 DK 2175851 T3 DK2175851 T3 DK 2175851T3 DK 08772643 T DK08772643 T DK 08772643T DK 2175851 T3 DK2175851 T3 DK 2175851T3
Authority
DK
Denmark
Prior art keywords
cinema
treatment
cinema treatment
Prior art date
Application number
DK08772643.6T
Other languages
Danish (da)
English (en)
Inventor
Stuart Geoffrey Dashper
Eric Charles Reynolds
Paul David Veith
Ching Seng Ang
Original Assignee
Oral Health Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40228120&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2175851(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2007903788A external-priority patent/AU2007903788A0/en
Application filed by Oral Health Australia Pty Ltd filed Critical Oral Health Australia Pty Ltd
Application granted granted Critical
Publication of DK2175851T3 publication Critical patent/DK2175851T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK08772643.6T 2007-07-12 2008-07-11 Biofilmbehandling DK2175851T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2007903788A AU2007903788A0 (en) 2007-07-12 Biofilm treatment
PCT/AU2008/001017 WO2009006699A1 (en) 2007-07-12 2008-07-11 Biofilm treatment

Publications (1)

Publication Number Publication Date
DK2175851T3 true DK2175851T3 (da) 2013-07-15

Family

ID=40228120

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08772643.6T DK2175851T3 (da) 2007-07-12 2008-07-11 Biofilmbehandling

Country Status (13)

Country Link
US (2) US8241611B2 (enExample)
EP (2) EP2175851B1 (enExample)
JP (1) JP5476297B2 (enExample)
KR (2) KR101614938B1 (enExample)
CN (2) CN103357014A (enExample)
AU (1) AU2008274906B2 (enExample)
CA (1) CA2693695C (enExample)
DK (1) DK2175851T3 (enExample)
ES (2) ES2714008T3 (enExample)
NZ (2) NZ595252A (enExample)
PL (1) PL2175851T3 (enExample)
SG (1) SG183016A1 (enExample)
WO (1) WO2009006699A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO652897A0 (en) 1997-04-30 1997-05-29 University Of Melbourne, The Synthetic peptide constructs for the diagnosis and treatment of periodontitis
US8129500B2 (en) 1997-12-10 2012-03-06 Csl Limited Porphyromonas gingivalis polypeptides and nucleotides
EP2038297A4 (en) 2006-06-27 2010-03-03 Oral Health Australia Pty Ltd PORPHYROMONAS GINGIVALIS POLYPEPTIDES SUITABLE FOR PREVENTION OF PERIODONTITIS
EP2604692A1 (en) 2007-07-12 2013-06-19 Oral Health Australia Pty Ltd Immunology treatment for biofilms
WO2009006699A1 (en) 2007-07-12 2009-01-15 Oral Health Australia Pty Ltd Biofilm treatment
AU2009287340B2 (en) 2008-08-29 2015-03-19 Oral Health Australia Pty Ltd Prevention, treatment and diagnosis of P.gingivalis infection
AR076179A1 (es) * 2009-04-01 2011-05-26 Colgate Palmolive Co Composicion dentifrica no acuosa con vidrio bioaceptable y bioactivo y metodos de uso y fabricacion de la misma
US8140041B2 (en) * 2009-08-27 2012-03-20 Mediatek Inc. Tunable capacitive device with linearization technique employed therein
MY162557A (en) 2010-02-26 2017-06-15 Oral Health Australia Pty Ltd Treatment or prevention of infection
KR101352795B1 (ko) * 2010-02-26 2014-02-17 주식회사 나이벡 치아의 접합능을 향상시키기 위한 치과용 클린저 조성물
US20120052052A1 (en) * 2010-08-27 2012-03-01 The Regents Of The University Of Michigan Control of biofilm formation
US9549904B2 (en) 2012-06-06 2017-01-24 Thomas Bryan Method of destroying bacterial biofilm using sterile intravenous or intracavernous glycerin
US9480669B2 (en) 2015-01-06 2016-11-01 The Regents Of The University Of California Method of destroying and preventing bacterial and fungal biofilm by amino acid infusion
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
US11248040B2 (en) 2013-09-26 2022-02-15 Trellis Bioscience, Llc Binding moieties for biofilm remediation
US9795809B2 (en) 2013-12-23 2017-10-24 Embro Corporation Use of moss to improve dental health
EP3322408B1 (en) 2015-07-14 2022-06-08 The Research Institute at Nationwide Children's Hospital Novel formulation for the elimination of cariogenic and opportunistic pathogens within the oral cavity
WO2017023863A1 (en) 2015-07-31 2017-02-09 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
EP3365027B1 (en) * 2015-10-14 2022-03-30 Research Institute at Nationwide Children's Hospital Hu specific antibodies and their use in inhibiting biofilm
EP3565834B1 (en) 2017-01-04 2025-10-22 The Research Institute at Nationwide Children's Hospital Antibody fragments for the treatment of biofilm-related disorders
JP7514621B2 (ja) 2017-01-04 2024-07-11 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル Ｄｎａｂｉｉワクチンおよび強化された活性を有する抗体
WO2018226987A1 (en) 2017-06-07 2018-12-13 The Regents Of The University Of California Compositions for treating fungal and bacterial biofilms and methods of using the same
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
WO2020072993A1 (en) 2018-10-05 2020-04-09 Research Institute At Nationwide Children's Hospital Hmgb1 protein derivatives for the removal of biofilms cross-reference to related application
WO2020117755A1 (en) 2018-12-03 2020-06-11 The Regents Of The University Of California Compositions and methods for treating biofilms
US12109176B1 (en) 2023-04-20 2024-10-08 Thomas Bryan Effect of glycerol on biofilm forming bacteria and fungi that changes the microbes sensitivity to pro and anti-biofilm non-toxic, non-bonded plasma amino acids and amino acid derivatives

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4735801A (en) 1982-09-07 1988-04-05 Board Of Trustees Of Leland Stanford Jr. University Novel non-reverting salmonella live vaccines
US5210035A (en) 1980-05-19 1993-05-11 Board Of Trustees Of Leland Stanford Jr. University Non-reventing live vaccines
US4837151A (en) 1980-05-19 1989-06-06 The Board Of Trustees Of The Leland Stanford Junior University, Stanford University Live vaccines comprising two mutations and foreign antigen
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5830710A (en) 1988-09-08 1998-11-03 University Of Florida Cloned porphyromonas gingivalis genes and probes for the detection of periodontal disease
WO1994027606A1 (en) * 1993-05-28 1994-12-08 Unisearch Limited Method of treating helicobacter pylori infection
US5711937A (en) 1993-06-28 1998-01-27 Lion Corporation Oral composition
EP0717747B1 (en) 1993-09-10 2003-06-04 The University Of Georgia Research Foundation, Inc. Porphyromonas gingivalis arginine-specific proteinase coding sequences
US5523390A (en) 1993-09-10 1996-06-04 University Of Georgia Research Foundation, Inc. Porphyromonas gingivalis arginine-specific proteinase
US5475097A (en) 1993-10-21 1995-12-12 University Of Georgia Research Foundation, Inc. Lysine-specific Porphyromonas gingivalis proteinase
US6017532A (en) 1993-09-10 2000-01-25 University Of Georgia Research Foundation, Inc. Porphyromonas gingivalis arginine-specific proteinase
JPH0797395A (ja) 1993-09-28 1995-04-11 Kyowa Medex Co Ltd ポルフイロモナス・ジンジバリス線毛蛋白質の配列を含有するペプチド類及びその用途
US5948636A (en) 1994-03-29 1999-09-07 Kyowa Hakko Kogyo Co., Ltd. DNA and host cells encoding a cell surface protein of porphyromonas gingivalis
AUPN627595A0 (en) 1995-10-30 1995-11-23 University Of Melbourne, The Diagnostics and treatments of periodontal disease
US6129917A (en) 1996-03-22 2000-10-10 The University Of Georgia Research Foundation, Inc. Immunogenic compositions comprising porphyromonas gingivalis proteins and/or peptides and methods
AUPN901296A0 (en) 1996-03-29 1996-04-26 University Of Melbourne, The Porphyromonas gingivalis antigens for the diagnosis and treatment of periodontitis
US7341727B1 (en) 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
AUPO652897A0 (en) 1997-04-30 1997-05-29 University Of Melbourne, The Synthetic peptide constructs for the diagnosis and treatment of periodontitis
AUPP083997A0 (en) 1997-12-10 1998-01-08 Csl Limited Porphyromonas gingivalis nucleotides
NZ504811A (en) 1997-12-10 2003-10-31 Csl Ltd Porphorymonas gingivalis polypeptides and nucleotides
US8129500B2 (en) 1997-12-10 2012-03-06 Csl Limited Porphyromonas gingivalis polypeptides and nucleotides
US6444799B1 (en) 1997-12-31 2002-09-03 Csl Limited P. gingivalis polynucleotides and uses thereof
AUPP893999A0 (en) 1999-03-01 1999-03-25 Csl Limited Synthetic peptides containing protective epitopes for the treatment and prevention of periodontitis associated with porphyromonas gingivalis
WO2000067917A1 (en) 1999-05-12 2000-11-16 The General Hospital Corporation Permeabilizing biofilms
GB9913437D0 (en) 1999-06-09 1999-08-11 Medical Res Council Fusion proteins
AUPQ485999A0 (en) 1999-12-24 2000-02-03 Csl Limited P. gingivalis antigenic composition
AUPQ718200A0 (en) * 2000-04-28 2000-05-25 Csl Limited Porphyromonas gingivalis recombinant proteins and truncations
US6726898B2 (en) * 2000-11-17 2004-04-27 Gary R. Jernberg Local delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease
US6576226B1 (en) 2000-11-17 2003-06-10 Gary R. Jernberg Local delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease
US20030083287A1 (en) 2000-11-30 2003-05-01 Burgess Nicola A. ginS
AUPR575401A0 (en) * 2001-06-18 2001-07-12 Unisearch Limited Method of causing sloughing
GB2381449A (en) * 2001-10-31 2003-05-07 Smithkline Beecham Plc Oral hygiene compositions comprising an electron acceptor
JP2003192616A (ja) 2001-12-27 2003-07-09 Univ Nihon 歯周病用ｄｎａワクチン
JP2003286191A (ja) 2002-03-27 2003-10-07 Univ Nihon 歯周病用粘膜免疫ワクチン
WO2004083425A1 (ja) 2003-03-17 2004-09-30 Kirin Beer Kabushiki Kaisha 歯周病治療剤
US7416852B2 (en) 2003-08-15 2008-08-26 University Of Florida Research Foundation Identification of Porphyromonas gingivalis virulence polynucleotides for diagnosis, treatment, and monitoring of periodontal diseases
JP2007520718A (ja) 2004-02-06 2007-07-26 カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ 治療可能性のあるアドヘシンおよびアドヘシン様タンパク質を同定するためのコンピュータを利用した方法
US20070098649A1 (en) * 2004-03-22 2007-05-03 The Board Of Trustees Of The University Of Illinois Method and composition for controlling oral pathogens
EP1799705A4 (en) 2004-09-23 2008-11-05 Univ Melbourne Antigenic complex for the diagnosis and treatment of porphyromonas gingivalis infection
WO2008016385A2 (en) 2006-01-20 2008-02-07 The University Of Washington Deacylase polypeptides, deacylase polynucleotides, and methods of use thereof
EP2038297A4 (en) * 2006-06-27 2010-03-03 Oral Health Australia Pty Ltd PORPHYROMONAS GINGIVALIS POLYPEPTIDES SUITABLE FOR PREVENTION OF PERIODONTITIS
WO2008124646A2 (en) 2007-04-06 2008-10-16 The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services Use of amyloid proteins as vaccine scaffolds
EP2604692A1 (en) 2007-07-12 2013-06-19 Oral Health Australia Pty Ltd Immunology treatment for biofilms
WO2009006699A1 (en) 2007-07-12 2009-01-15 Oral Health Australia Pty Ltd Biofilm treatment
AU2009287340B2 (en) 2008-08-29 2015-03-19 Oral Health Australia Pty Ltd Prevention, treatment and diagnosis of P.gingivalis infection
KR20120027535A (ko) * 2009-06-19 2012-03-21 오럴 헬스 오스트레일리아 피티와이 엘티디 카제인 유래 프로테아제 저해 펩타이드

Also Published As

Publication number Publication date
ES2432690T3 (es) 2013-12-04
EP2175851B1 (en) 2013-05-15
EP2638905A2 (en) 2013-09-18
CA2693695A1 (en) 2009-01-15
US8241611B2 (en) 2012-08-14
AU2008274906A1 (en) 2009-01-15
HK1143530A1 (en) 2011-01-07
KR101614938B1 (ko) 2016-04-22
US20100209362A1 (en) 2010-08-19
KR20160013240A (ko) 2016-02-03
EP2175851A4 (en) 2011-03-16
US8895019B2 (en) 2014-11-25
US20130028847A1 (en) 2013-01-31
CA2693695C (en) 2016-06-07
JP5476297B2 (ja) 2014-04-23
EP2638905A3 (en) 2014-03-05
NZ582474A (en) 2012-03-30
NZ595252A (en) 2013-11-29
CN101842097B (zh) 2013-06-19
EP2175851A1 (en) 2010-04-21
PL2175851T3 (pl) 2013-11-29
AU2008274906B2 (en) 2013-11-07
ES2714008T3 (es) 2019-05-24
JP2010532765A (ja) 2010-10-14
EP2638905B1 (en) 2019-01-16
CN101842097A (zh) 2010-09-22
WO2009006699A1 (en) 2009-01-15
SG183016A1 (en) 2012-08-30
KR20100051656A (ko) 2010-05-17
CN103357014A (zh) 2013-10-23

Similar Documents

Publication Publication Date Title
DK2175851T3 (da) Biofilmbehandling
BRPI0821573A2 (pt) benzofuropirimidonas
ATE501136T1 (de) Imidazopyridinone
DE502007001207D1 (de) Elektrosaugkopf
DK2330887T3 (da) Behandlingsindretning
ATE514696T1 (de) Diphenyl-dihydro-imidazopyridinone
DE112008003636A5 (de) Mehrzuggruppierer
DE602008000923D1 (de) Einzelwaferätzgerät
BRPI0811451A2 (pt) Exopolissacarídeo
BRPI0814519A2 (pt) Organopolissiloxano
DE602008000749D1 (de) Buschschneider
BRPI0815547A2 (pt) Depsipeptídeos cícliocos
DK2173831T3 (da) Brøndbehandling
BRPI0812840A2 (pt) 2-imidazolinas
DE602008001234D1 (de) Bandmaterialzuführvorrichtung
AT505058A3 (de) Türschliesssystem
BRPI0812994A2 (pt) Microbiocidas
BRPI0818598A2 (pt) agentes terapêuticos - 802
DE602008001674D1 (de) Wimpernwickler
DE112008001216A5 (de) Magnetronplasmaanlage
DE502008001694D1 (de) Mitfahrhubwagen
DE112008003094A5 (de) Geomatte
HRP20160577T1 (hr) Liječenje osteoartritisa
DE112008003196A5 (de) Handpipettiergerät
DE602008000292D1 (de) Werkzeughaltepositioniervorrichtung